CD274 and neoplasm: An alternative approach involving immune therapy, which previously had been rejected by most physician scientists as ineffective and cumbersome, has regained favor as a result of new knowledge about the immune checkpoint receptor, PD-1 and its ligand, PD-L1, which regulate T-cell activity in the tumor microenvironment.